Apnimed Prices $192 Million IPO

Company Apnimed Event Type Initial Public Offering (Upsized Pricing) Modality Fixed-dose oral combination, once-nightly Asset AD109 (aroxybutynin 2.5 mg / atomoxetine 75 mg) Target Muscarinic receptors (antagonism) and noradrenergic upper-airway dilator-muscle activity Disease Area Obstructive sleep apnea Summary Apnimed priced an upsized initial public offering…